AstraZeneca plc (LSE:AZN; NYSE:AZN) appears to have more clinical compounds targeting a wider range of novel targets/mechanisms of action for asthma and chronic obstructive pulmonary disease (COPD) than either GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and